Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Safety and Efficacy of CXA-10 in Pulmonary Arterial Hypertension (Extension of CXA-10-301)
2019-002414-40Phase 2Terminated
- Sponsor
- Complexa Therapeutics
- Start
- Oct 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of 10-nitro-oleic acid in pulmonary arterial hypertension (PAH), sponsored by Complexa Therapeutics. Primary endpoint: Primary safety endpoints. Started Oct 2019; status: terminated.
02
Drugs
10-nitro-oleic acid
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on 2019-002414-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-002414-40.